1. Mano MS, çitaku FT, Barach P: Implementing Multidisciplinary Tumor Boards in Oncology: a Narrative Review. Future Oncology 18:375-384, 2021
2. Walraven JEW, Desar IME, Hoeven van der JJM, et al: Analysis of 105.000 patients with cancer: have they been discussed in oncologic multidisciplinary team meetings? A nationwide population-based study in the Netherlands. European Journal of Cancer 121:85-93, 2019
3. Fehervari M, Hamrang-Yousefi S, Fadel MG, et al: A systematic review of colorectal multidisciplinary team meetings: an international comparison. BJS Open 5, 2021
4. Prades J, Remue E, van Hoof E, et al: Is it worth reorganising cancer services on the basis of multidisciplinary teams (MDTs)? A systematic review of the objectives and organisation of MDTs and their impact on patient outcomes. Health Policy 119:464-474, 2015
5. Specchia ML, Frisicale EM, Carini E, et al: The impact of tumor board on cancer care: evidence from an umbrella review. BMC Health Serv Res 20:73, 2020
6. Freytag M, Herrlinger U, Hauser S, et al: Higher number of multidisciplinary tumor board meetings per case leads to improved clinical outcome. BMC Cancer 20, 2020
7. Wright FC, De Vito C, Langer B, et al: Multidisciplinary cancer conferences: A systematic review and development of practice standards. European Journal of Cancer 43:1002-1010, 2007
8. Basta YL, Bolle S, Fockens P, et al: The Value of Multidisciplinary Team Meetings for Patients with Gastrointestinal Malignancies: A Systematic Review. Annals of Surgical Oncology 24:2669-2678, 2017
9. Borras JM, Albreht T, Audisio R, et al: Policy statement on multidisciplinary cancer care. European Journal of Cancer 50:475-480, 2014
10. Zhao H, Zhang N, Ho V, et al: Adherence to treatment guidelines and survival for older patients with stage II or III colon cancer in Texas from 2001 through 2011. Cancer 124:679-687, 2017
11. Thiels CA, Hanson KT, Habermann EB, et al: Integrated cancer networks improve compliance with national guidelines and outcomes for resectable gastric cancer. Cancer 126:1283-1294, 2019
12. Jaap K, Fluck M, Hunsinger M, et al: Analyzing the Impact of Compliance with National Guidelines for Pancreatic Cancer Care Using the National Cancer Database. Journal of Gastrointestinal Surgery 22:1358-1364, 2018
13. Worhunsky DJ, Ma Y, Zak Y, et al: Compliance With Gastric Cancer Guidelines is Associated With Improved Outcomes. Journal of the National Comprehensive Cancer Network 13:319-325, 2015
14. Walter J, Moeller C, Resuli B, et al: Guideline adherence of tumor board recommendations in lung cancer and transfer into clinical practice. Journal of Cancer Research and Clinical Oncology 149:11679-11688, 2023
15. Krause A, Stocker G, Gockel I, et al: Guideline adherence and implementation of tumor board therapy recommendations for patients with gastrointestinal cancer. Journal of Cancer Research and Clinical Oncology 149:1231-1240, 2022
16. Pfister DG, Rubin DM, Elkin EB, et al: Risk Adjusting Survival Outcomes in Hospitals That Treat Patients With Cancer Without Information on Cancer Stage. JAMA Oncology 1, 2015
17. Wong AR, Sun V, George K, et al: Barriers to Participation in Therapeutic Clinical Trials as Perceived by Community Oncologists. JCO Oncology Practice 16:e849-e858, 2020
18. The State of Cancer Care in America, 2014: A Report by the American Society of Clinical Oncology. Journal of Oncology Practice 10:119-142, 2014
19. Keating NL, Landrum MB, Lamont EB, et al: Tumor Boards and the Quality of Cancer Care. JNCI Journal of the National Cancer Institute 105:113-121, 2012
20. von Elm E, Altman DG, Egger M, et al: The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies. PLoS Medicine 4, 2007
21. Onkologie L: S3-Leitlinie Kolorektales Karzinom. Langversion 2.1.–Januar. 2019. AWMF-Registernummer: 021/007OL, 2021
22. Onkologie L: S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms, Version 4.4, 2021, AWMF Registernummer: 032-045OL. Accessed April 4, 2021
23. Braulke F, Kober K, Rieken S, et al: Adherence to interdisciplinary tumor board recommendations as an expression of quality-assured patient care: results of a bicentric German analysis. Journal of Cancer Research and Clinical Oncology 149:14775-14784, 2023
24. Hollunder S, Herrlinger U, Zipfel M, et al: Cross-sectional increase of adherence to multidisciplinary tumor board decisions. BMC Cancer 18, 2018
25. Buuren Sv, Groothuis-Oudshoorn K: mice: Multivariate Imputation by Chained Equations inR. Journal of Statistical Software 45, 2011
26. Brant R: Assessing Proportionality in the Proportional Odds Model for Ordinal Logistic Regression. Biometrics 46, 1990
27. Lamb BW, Brown KF, Nagpal K, et al: Quality of Care Management Decisions by Multidisciplinary Cancer Teams: A Systematic Review. Annals of Surgical Oncology 18:2116-2125, 2011
28. Lamb BW, Wong HWL, Vincent C, et al: Teamwork and team performance in multidisciplinary cancer teams: development and evaluation of an observational assessment tool. BMJ Quality & Safety 20:849-856, 2011
29. Ambroggi M, Biasini C, Del Giovane C, et al: Distance as a Barrier to Cancer Diagnosis and Treatment: Review of the Literature. The Oncologist 20:1378-1385, 2015
30. Bühn S, Holstiege J, Pieper D: Are patients willing to accept longer travel times to decrease their risk associated with surgical procedures? A systematic review. BMC Public Health 20, 2020
31. Brauer DG, Strand MS, Sanford DE, et al: Utility of a multidisciplinary tumor board in the management of pancreatic and upper gastrointestinal diseases: an observational study. Hpb 19:133-139, 2017
32. Sedrak MS, Freedman RA, Cohen HJ, et al: Older adult participation in cancer clinical trials: A systematic review of barriers and interventions. CA: A Cancer Journal for Clinicians 71:78-92, 2020
33. Booth CM, Tannock IF: Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. British Journal of Cancer 110:551-555, 2014
34. Bahadoer RR, Dijkstra EA, van Etten B, et al: Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. The Lancet Oncology 22:29-42, 2021
35. Ronden MI, Bahce I, Hashemi SMS, et al: Factors influencing multi-disciplinary tumor board recommendations in stage III non-small cell lung cancer. Lung Cancer 152:149-156, 2021
36. Hines RB, Barrett A, Twumasi-Ankrah P, et al: Predictors of Guideline Treatment Nonadherence and the Impact on Survival in Patients With Colorectal Cancer. Journal of the National Comprehensive Cancer Network 13:51-60, 2015
37. Riley RD, Cole TJ, Deeks J, et al: On the 12th Day of Christmas, a Statistician Sent to Me. Bmj, 2022
38. Gooiker GA, van Gijn W, Wouters MWJM, et al: Systematic review and meta-analysis of the volume–outcome relationship in pancreatic surgery. British Journal of Surgery 98:485-494, 2011
39. Voeten DM, Gisbertz SS, Ruurda JP, et al: Overall Volume Trends in Esophageal Cancer Surgery Results From the Dutch Upper Gastrointestinal Cancer Audit. Annals of Surgery 274:449-458, 2021
40. Grose D, Devereux G, Brown L, et al: Variation in Comorbidity and Clinical Management in Patients Newly Diagnosed with Lung Cancer in Four Scottish Centers. Journal of Thoracic Oncology 6:500-509, 2011
41. Tucker TC, Charlton ME, Schroeder MC, et al: Improving the Quality of Cancer Care in Community Hospitals. Annals of Surgical Oncology 28:632-638, 2020